The DOI matches its Crossref record; 52 of the 54 references it cites were found in a registry or an index.
Somatic mutations affect key pathways in lung adenocarcinoma
Open accessAbstract
Determining the genetic basis of cancer requires comprehensive analyses of large collections of histopathologically well-classified primary tumours. Here we report the results of a collaborative study to discover somatic mutations in 188 human lung adenocarcinomas. DNA sequencing of 623 genes with known or potential relationships to cancer revealed more than 1,000 somatic mutations across the samples. Our analysis identified 26 genes that are mutated at significantly high frequencies and thus are probably involved in carcinogenesis. The frequently mutated genes include tyrosine kinases, among them the EGFR homologue ERBB4; multiple ephrin receptor genes, notably EPHA3; vascular endothelial growth factor receptor KDR; and NTRK genes. These data provide evidence of somatic mutations in primary lung adenocarcinoma for several tumour suppressor genes involved in other cancers--including NF1, APC, RB1 and ATM--and for sequence changes in PTPRD as well as the frequently deleted gene LRP1B. The observed mutational profiles correlate with clinical features, smoking status and DNA repair defects. These results are reinforced by data integration including single nucleotide polymorphism array and gene expression array. Our findings shed further light on several important signalling pathways involved in lung adenocarcinoma, and suggest new molecular targets for treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“While gain of 7p and loss of 8p have been previously reported to occur specifically in EGFR mutated adenocarcinomas16, 17, gain of 16p was a novel association.”
From Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredIn the citing paper
“KRAS mutations predominate in NSCLCs, accounting for ~78% of all RAS mutations found in such tumours17. The activating missense KRAS mutations that occur in ~25% of NSCLCs19–23 are typically mutually exclusive with other clinically actionable driver mutations, such as those in EGFR, BRAF and ALK24.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [22]
In the citing paper
“Importantly, large-scale profiling studies utilizing either whole exome sequencing or broad targeted sequencing panels in NSCLC tumors have revealed multiple non-random patterns of co-occurring or mutually exclusive mutations, which typically vary depending on the particular oncogenic driver mutation15, 34, 58–62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [60]
In the citing paper
“Activating mutations in KRAS are the most prevalent oncogenic driver event in both early-stage and metastatic LUAD, occurring in 25–32% of tumors34, 59, 60, 62, 67.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [60]
In the citing paper
“Similarly, mutations in ERBB4 were identified in cancer, particularly melanoma (Prickett et al., 2009), lung adenocarcinoma (Ding et al., 2008), and medulloblastoma (Gilbertson et al., 2001).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Ding et al., 2008
In the citing paper
“Gain/amplification of the mutant EGFR allele has previously been reported to frequently occur in LAC and is known to drive tumor progression17.”
From Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis (2019) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,077
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,710
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Self-citationEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citationEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Self-citationPao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Self-citationThe Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Patterns of somatic mutation in human cancer genomes
Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,143
Cited by
Sorted by citations
Items 301–400 of 1,007
Assoun, S., Théou–Anton, N., Nguenang, M., Cazes, A., Danel, C. J., Abbar, B., Pluvy, J., Gounant, V., Khalil, A., Namour, C., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.04.005 · Cited by 171
Targeting radiation-resistant hypoxic tumour cells through ATR inhibition
Pires, I. M., Olcina, M. M., Anbalagan, S., Pollard, J. R., Reaper, P. M., Charlton, P., McKenna, W. G., & Hammond, E. M. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.265 · Cited by 175
Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications
Rudin, C. M., Ávila-Tang, É., Harris, C. C., Herman, J. G., Hirsch, F. R., Pao, W. J., Schwartz, A. G., Vähäkangas, K., & Samet, J. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0377 · Cited by 175
Self-citationZhou, M., Guo, M., He, D., Wang, X., Cui, Y., Yang, H., Hao, D., & Sun, J. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0556-3 · Cited by 171
Choudhury, N. J., Campanile, A., Antic, T., Yap, K. L., Fitzpatrick, C. A., Wade, J. L., Karrison, T., Stadler, W. M., Nakamura, Y., & O’Donnell, P. H. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.3047 · Cited by 170
An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer
Maertens, O., & Cichowski, K. M. (2014) · Advances in Biological Regulation · doi:10.1016/j.jbior.2014.04.002 · Cited by 171
Dupuy, A. J., Rogers, L. M., Kim, J., Nannapaneni, K., Starr, T. K., Liu, P., Largaespada, D. A., Scheetz, T. E., Jenkins, N. A., & Copeland, N. G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1135 · Cited by 172
Fagan, R. J., & Dingwall, A. K. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.024 · Cited by 177
Gao, M., Duan, L., Luo, J., Zhang, L., Lu, X., Zhang, Y., Zhang, Z., Tu, Z., Xu, Y., Ren, X., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301824k · Cited by 168
Human rRNA Gene Clusters Are Recombinational Hotspots in Cancer
Stults, D. M., Killen, M. W., Williamson, E. P., Hourigan, J. S., Vargas, H. D., Arnold, S. M., Moscow, J. A., & Pierce, A. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2680 · Cited by 169
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
Leonetti, A., Facchinetti, F., Rossi, G., Minari, R., Conti, A., Friboulet, L., Tiseo, M., & Planchard, D. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.006 · Cited by 179
The AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC
Hollstein, P. E., Eichner, L. J., Brun, S. N., Kamireddy, A., Svensson, R. U., Vera, L. I., Ross, D. S., Rymoff, T. J., Hutchins, A., Galvez, H. M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1261 · Cited by 168
Advances in the preclinical testing of cancer therapeutic hypotheses
Caponigro, G., & Sellers, W. R. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3385 · Cited by 165
Gerber, D. E., Camidge, D. R., Morgensztern, D., Cetnar, J., Kelly, R. J., Ramalingam, S. S., Spigel, D. R., Jeong, W., Scaglioni, P. P., Zhang, S., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.033 · Cited by 167
Molina-Arcas, M., Hancock, D. C., Sheridan, C., Kumar, M. S., & Downward, J. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0446 · Cited by 157
Chronotherapy and the molecular clock: Clinical implications in oncology☆
Innominato, P. F., Lévi, F., & Bjarnason, G. A. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.06.002 · Cited by 168
Targeting transcription cycles in cancer
Vervoort, S. J., Devlin, J. R., Kwiatkowski, N. P., Teng, M., Gray, N. S., & Johnstone, R. W. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00411-8 · Cited by 170
Pacheco-Pinedo, E. C., Durham, A. C., Stewart, K. M., Goss, A. M., Lu, M. M., DeMayo, F. J., & Morrisey, E. E. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44871 · Cited by 164
Neurofibromatosis type 1-associated tumours: Their somatic mutational spectrum and pathogenesis
Spyk, S. L.-V., Thomas, N. S. T., Cooper, D. N., & Upadhyaya, M. (2011) · Human Genomics · doi:10.1186/1479-7364-5-6-623 · Cited by 163
KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer
Krall, E. B., Wang, B., Munoz, D. M., Ilic, N., Raghavan, S., Niederst, M. J., Yu, K., Ruddy, D. A., Aguirre, A. J., Kim, J. W., et al. (2017) · eLife · doi:10.7554/elife.18970 · Cited by 160
“Introduction The receptor tyrosine kinase (RTK)/ mitogen-activated protein kinase (MAPK) pathway plays an important role in the development of lung and other cancers, with the frequent occurrence of mutations or copy number alterations in multiple nodes of this pathway (Ding et al., 2008; Imielinski et al., 2012).”
BackgroundTargeting the DNA Damage Response in Cancer
Ljungman, M. E. (2009) · Chemical Reviews · doi:10.1021/cr900047g · Cited by 164
Yasuda, H., de Figueiredo‐Pontes, L. L., Kobayashi, S. S., & Costa, D. B. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182570919 · Cited by 162
A step-by-step microRNA guide to cancer development and metastasis
Markopoulos, G. S., Roupakia, E., Tokamani, M., Chavdoula, E., Hatziapostolou, M., Polytarchou, C., Marcu, K. B., Papavassiliou, A. G., Sandaltzopoulos, R., & Kolettas, E. (2017) · Cellular Oncology · doi:10.1007/s13402-017-0341-9 · Cited by 164
Wnt signaling in lung development, regeneration, and disease progression
Aros, C. J., Pantoja, C. J., & Gomperts, B. N. (2021) · Communications Biology · doi:10.1038/s42003-021-02118-w · Cited by 171
The mutational landscape of phosphorylation signaling in cancer
Reimand, J., Wagih, O., & Bader, G. D. (2013) · Scientific Reports · doi:10.1038/srep02651 · Cited by 163
Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer
Herter-Sprie, G. S., Koyama, S., Korideck, H., Hai, J., Deng, J., Li, Y. Y., Buczkowski, K. A., Grant, A. K., Ullas, S., Rhee, K., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87415 · Cited by 164
Lee, J., Kim, T. M., Lee, S., Kim, D., Kim, S., Jeon, Y., Chung, D. H., Kim, W. H., Kim, Y. T., Yang, S.-C., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182208fc2 · Cited by 160
Gorlick, R., & Khanna, C. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.77 · Cited by 157
Personalized medicine in lung cancer: what we need to know
Mok, T. S. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.126 · Cited by 165
Seipin: from human disease to molecular mechanism
Cartwright, B. R., & Goodman, J. M. (2012) · Journal of Lipid Research · doi:10.1194/jlr.r023754 · Cited by 160
Global networks of functional coupling in eukaryotes from comprehensive data integrationPreprint
Alexeyenko, A., & Sonnhammer, E. L. L. (2009) · Genome Research · doi:10.1101/gr.087528.108 · Cited by 158
Clinicopathological relevance of BRAF mutations in human cancer
Pakneshan, S., Salajegheh, A., Anthony Smith, R., & King-Yin Lam, A. (2013) · Pathology · doi:10.1097/pat.0b013e328360b61d · Cited by 156
Dhanasekaran, S. M., Balbin, O. A., Chen, G., Nadal, E., Sundaram, S. K., Pan, J., Veeneman, B. A., Cao, X., Malik, R., Vats, P., et al. (2014) · Nature Communications · doi:10.1038/ncomms6893 · Cited by 154
Self-citationSomwar, R., Erdjument‐Bromage, H., Larsson, E., Shum, D., Lockwood, W. W., Yang, G., Sander, C., Ouerfelli, O., Tempst, P., Djaballah, H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113554108 · Cited by 155
Self-citationTug-of-war between driver and passenger mutations in cancer and other adaptive processes
McFarland, C. D., Mirny, L. A., & Korolev, K. S. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404341111 · Cited by 163
Chuang, C.-H., Greenside, P., Rogers, Z. N., Brady Jennifer, J., Yang, D., Ma, R. K., Caswell, D. R., Chiou, S., Winters, A. F., Grüner, B. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4285 · Cited by 153
Stepwise pathogenic evolution of Mycobacterium abscessus
Bryant, J. M., Brown, K., Burbaud, S., Everall, I., Belardinelli, J. M., Rodriguez-Rincon, D., Grogono, D., Peterson, C. M., Verma, D., Evans, I., et al. (2021) · Science · doi:10.1126/science.abb8699 · Cited by 159
Gallo, L. H., Nelson, K. N., Meyer, A. N., & Donoghue, D. J. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.03.003 · Cited by 155
Efficient methods for identifying mutated driver pathways in cancer
Zhao, J., Zhang, S., Wu, L., & Zhang, X.-S. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts564 · Cited by 155
Tumor suppressor functions of FBW7 in cancer development and progression
Wang, Z. P., Inuzuka, H., Zhong, J., Wan, L., Fukushima, H., Sarkar, F. H., & Wei, W. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.03.017 · Cited by 154
Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed
Yosaatmadja, Y., Silva, S., Dickson, J. M. J. J., Patterson, A. V., Smaill, J. B., Flanagan, J. U., McKeage, M. J., & Squire, C. J. (2015) · Journal of Structural Biology · doi:10.1016/j.jsb.2015.10.018 · Cited by 150
Ron, C., Khatri, P., Mazur, P. K., Polin, M., Zheng, Y., Vaka, D., Hoang, C. D., Shrager, J. B., Xu, Y., Vicent, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2775 · Cited by 155
Wynes, M. W., Hinz, T. K., Gao, D., Martini, M., Marek, L. A., Ware, K. E., Edwards, M. G., Böhm, D., Perner, S., Helfrich, B. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3060 · Cited by 156
Girard, N., Ostrovnaya, I., Lau, C. C., Park, B. J., Ladanyi, M., Finley, D. J., Deshpande, C. G., Rusch, V. W., Orlow, I., Travis, W. D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0594 · Cited by 152
Self-citationCancer Genes in Lung Cancer: Racial Disparities: Are There Any?
El-Telbany, A., & Ma, P. C. (2012) · Genes & Cancer · doi:10.1177/1947601912465177 · Cited by 156
McCoach, C. E., Blakely, C. M., Banks, K. C., Levy, B. P., Chue, B. M.-F., Raymond, V. M., Le, A. T., Lee, C. E., Diaz, J., Waqar, S. N., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2588 · Cited by 152
Ricciuti, B., Recondo, G., Spurr, L. F., Li, Y. Y., Lamberti, G., Venkatraman, D., Umeton, R., Cherniack, A. D., Nishino, M., Sholl, L. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3529 · Cited by 154
Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers
Tomizawa, K., Suda, K., Onozato, R., Kosaka, T., Endoh, H., Sekido, Y., Shigematsu, H., Kuwano, H., Yatabe, Y., & Mitsudomi, T. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.01.014 · Cited by 151
The Cancer Cell Map Initiative: Defining the Hallmark Networks of Cancer
Krogan, N. J., Lippman, S. M., Agard, D. A., Ashworth, A., & Ideker, T. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.05.008 · Cited by 154
Bai, A., Meetze, K. A., Vo, N. N. Y., Kollipara, S., Mazsa, E. K., Winston, W. M., Weiler, S., Poling, L. L., Chen, T., Ismail, N. S., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1489 · Cited by 151
Kim, H. R., Shim, H. S., Chung, J.-H., Lee, Y. J., Hong, Y. K., Rha, S. Y., Kim, S. H., Ha, S., Kim, S. K., Chung, K. S., et al. (2011) · Cancer · doi:10.1002/cncr.26311 · Cited by 149
Valencia, K., Ormazabal, C., Zandueta, C., Luis-Ravelo, D., Antón, I., Pajares, M. J., Agorreta, J., Montuenga, L. M., Martínez-Canarias, S., Leitinger, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1686 · Cited by 149
Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model
Xia, Y., Yeddula, N., Leblanc, M., Ke, E., Zhang, Y., Oldfield, E., Shaw, R. J., & Verma, I. M. (2012) · Nature Cell Biology · doi:10.1038/ncb2428 · Cited by 152
Lung Cancer Subtypes Generate Unique Immune Responses
Busch, S., Hanke, M. L., Kargl, J., Metz, H. E., MacPherson, D. P., & Houghton, A. M. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600576 · Cited by 147
Rogers, Z. N., McFarland, C. D., Winters, I. P., Naranjo, S., Chuang, C.-H., Petrov, D. A., & Winslow, M. M. (2017) · Nature Methods · doi:10.1038/nmeth.4297 · Cited by 141
Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma
Burnichon, N., Buffet, A., Parfait, B., Letouzé, É., Laurendeau, I., Loriot, C., Pasmant, É., Abermil, N., Valeyrie‐Allanore, L., Bertherat, J. Y., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds374 · Cited by 159
Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapy
Manic, G., Obrist, F., Sistigu, A., & Vitale, I. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1012976 · Cited by 152
Disruption of PH–kinase domain interactions leads to oncogenic activation of AKT in human cancers
Parikh, C., Janakiraman, V., Wu, W., Foo, C. K., Kljavin, N. M., Chaudhuri, S., Stawiski, E. W., Lee, B., Lin, J. M., Li, H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204384109 · Cited by 147
Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities
Sanjiv, K., Hagenkort, A., Calderón‐Montaño, J. M., Koolmeister, T., Reaper, P. M., Mortusewicz, O., Jacques, S. A., Kuiper, R., Schultz, N., Scobie, M., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.12.032 · Cited by 147
The Conundrum of Genetic “Drivers” in Benign Conditions
Kato, S., Lippman, S. M., Flaherty, K. T., & Kurzrock, R. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw036 · Cited by 149
Izumchenko, E., Chang, X., Brait, M., Fertig, E. J., Kagohara, L. T., Bedi, A., Marchionni, L., Agrawal, N., Ravi, R. K., Jones, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms9258 · Cited by 148
Prospects for pharmacological targeting of pseudokinases
Kung, J. E., & Jura, N. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0018-3 · Cited by 144
Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells
Poh, A. R., O’Donoghue, R. J. J., & Ernst, M. (2015) · Oncotarget · doi:10.18632/oncotarget.4199 · Cited by 147
Ekumi, K. M., Paculová, H., Lenasi, T., Pospíchalová, V., Bösken, C. A., Rybaříková, J., Bryja, V., Geyer, M., Blažek, D., & Barborič, M. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv101 · Cited by 145
Analysis of next-generation genomic data in cancer: accomplishments and challenges
Ding, L., Wendl, M. C., Koboldt, D. C., & Mardis, E. R. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq391 · Cited by 148
Self-citationSchneider, M. A., Christopoulos, P., Muley, T., Warth, A., Klingmüller, U., Thomas, M., Herth, F. J. F., Dienemann, H., Mueller, N. S., Theis, F. J., et al. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3834 · Cited by 144
Yan, T., Cui, H., Zhou, Y., Yang, B. J., Kong, P., Zhang, Y., Liu, Y., Wang, B., Cheng, Y., Li, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09255-1 · Cited by 145
Akiri, G., Cherian, M. M., Vijayakumar, S., Liu, G., Bafico, A., & Aaronson, S. A. (2009) · Oncogene · doi:10.1038/onc.2009.82 · Cited by 143
Casagrande, A., & Pederiva, F. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.023 · Cited by 143
Pfister, N. T., Fomin, V., Regunath, K., Zhou, J. Y., Zhou, W., Silwal‐Pandit, L., Freed-Pastor, W. A., Laptenko, O., Neo, S. P., Bargonetti, J., et al. (2015) · Genes & Development · doi:10.1101/gad.263202.115 · Cited by 149
Konstantinidou, G., Bey, E. A., Rabellino, A., Schuster, K., Maira, M. S., Gazdar, A. F., Amici, A., Boothman, D. A., & Scaglioni, P. P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0823 · Cited by 142
Existing and Emerging Technologies for Tumor Genomic Profiling
MacConaill, L. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.5948 · Cited by 144
Characteristics of Lung Cancers Harboring NRAS Mutations
Ohashi, K., Sequist, L. V. D., Arcila, M. E., Lovly, C. M., Chen, X., Rudin, C. M., Morán, T., Camidge, D. R., Vnencak‐Jones, C. L., Berry, L. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3173 · Cited by 147
Self-citationPI3K/Akt/mTOR inhibitors in breast cancer.
Lee, J. J. X., Loh, K. W.-J., & Yap, Y. S. (2015) · Europe PMC (PubMed Central) · doi:10.7497/j.issn.2095-3941.2015.0089 · Cited by 230
Oncogenic alterations in advanced NSCLC: a molecular super-highway
Friedlaender, A., Pérol, M., Banna, G. L., Parikh, K., & Addeo, A. (2024) · Biomarker Research · doi:10.1186/s40364-024-00566-0 · Cited by 150
Curtis, S. J., Sinkevicius, K. W., Li, D., Lau, A. N., Roach, R. R., Zamponi, R., Woolfenden, A. E., Kirsch, D. G., Wong, K., & Kim, C. F. (2010) · Cell stem cell · doi:10.1016/j.stem.2010.05.021 · Cited by 144
Small molecule promotes β-catenin citrullination and inhibits Wnt signaling in cancer
Qu, Y., Olsen, J. R., Xing, Y., Cheng, P. F., Levesque, M. P., Brokstad, K. A., Hoffman, P. S., Oyan, A. M., Zhang, W., Kalland, K., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2510 · Cited by 143
Clinical outcomes in non‐small‐cell lung cancer patients with EGFR mutations: pooled analysis
Paz-Ares, L. G., Soulières, D., Melezínek, I., Moecks, J., Keil, L., Mok, T. S. K., Rosell, R., & Klughammer, B. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00991.x · Cited by 141
Nongenetic Evolution Drives Lung Adenocarcinoma Spatial Heterogeneity and Progression
Tavernari, D., Battistello, E., Dheilly, E., Petruzzella, A. S., Mina, M., Sordet‐Dessimoz, J., Peters, S., Krueger, T., Gfeller, D., Riggi, N., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1274 · Cited by 138
KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma
Nadal, E., Chen, G., Prensner, J. R., Shiratsuchi, H., Sam, C., Zhao, L., Kalemkerian, G. P., Brenner, D. E., Lin, J., Reddy, R. M., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000305 · Cited by 147
Self-citationEnhanced construction of gene regulatory networks using hub gene information
Yu, D., Lim, J., Wang, X., Liang, F., & Xiao, G. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1576-1 · Cited by 137
Dysregulation of RNA polymerase I transcription during disease
Hannan, K. M., Sanij, E., Rothblum, L. I., Hannan, R. D., & Pearson, R. B. (2012) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2012.10.014 · Cited by 137
Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014
Morgensztern, D., Campo, M. J., Dahlberg, S. E., Doebele, R. C., Garon, E. B., Gerber, D. E., Goldberg, S. B., Hammerman, P. S., Heist, R. S., Hensing, T. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000405 · Cited by 138
The RasGAP Gene, RASAL2, Is a Tumor and Metastasis Suppressor
McLaughlin, S. K., Olsen, S. N., Dake, B. T., Raedt, T. D., Lim, E., Bronson, R. T., Beroukhim, R., Polyák, K., Brown, M. A., Kuperwasser, C., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.004 · Cited by 137
Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling
Ferguson, H. R., Smith, M. P., & Francavilla, C. (2021) · Cells · doi:10.3390/cells10051201 · Cited by 142
Network enrichment analysis: extension of gene-set enrichment analysis to gene networks
Alexeyenko, A., Lee, W., Pernemalm, M., Guegan, J., Dessen, P., Lazar, V., Lehtiö, J., & Yudi Pawitan, Y. (2012) · BMC Bioinformatics · doi:10.1186/1471-2105-13-226 · Cited by 135
Genetic Mutations Associated with Cigarette Smoking in Pancreatic Cancer
Blackford, A. L., Parmigiani, G., Kensler, T. W., Wolfgang, C. L., Jones, S., Zhang, X., Parsons, D. W., Lin, J., Leary, R. J., Eshleman, J. R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0015 · Cited by 134
Kamel, H. F. M., & Al-Amodi, H. S. A. B. (2017) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.11.005 · Cited by 137
Targeting the KRAS Pathway in Non-Small Cell Lung Cancer
Tomasini, P., Walia, P., Labbé, C., Jao, K., & Leighl, N. B. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0084 · Cited by 135
Helsten, T. L., Schwaederle, M. C., & Kurzrock, R. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9579-8 · Cited by 132
Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers
Litvak, A. M., Paik, P. K., Woo, K. M., Sima, C. S., Hellmann, M. D., Arcila, M. E., Ladanyi, M., Rudin, C. M., Kris, M. G., & Riely, G. J. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000344 · Cited by 132
Self-citationNovel Therapeutic Targets in Non-small Cell Lung Cancer
Jankú, F., Garrido‐Laguna, I., Petruzelka, L. B., Stewart, D. J., & Kurzrock, R. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822944b3 · Cited by 133
Collagen recognition and transmembrane signalling by discoidin domain receptors
Carafoli, F., & Hohenester, E. (2012) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2012.10.014 · Cited by 131
Cheung, H. W., Du, J., Boehm, J. S., He, F., Weir, B. A., Wang, X., Butaney, M., Sequist, L. V. D., Luo, B., Engelman, J. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0046 · Cited by 131
Self-citationFenofibrate prevents skeletal muscle loss in mice with lung cancer
Goncalves, M. D., Hwang, S., Pauli, C., Murphy, C. J., Cheng, Z., Hopkins, B. D., Wu, D., Loughran, R. M., Emerling, B. M., Zhang, G., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714703115 · Cited by 133
Voelkerding, K. V., Dames, S. A., & Durtschi, J. (2010) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.100043 · Cited by 137
Genetic Characterization of the Soybean Nested Association Mapping Population
Song, Q., Yan, L., Quigley, C., Jordan, B. D., Fickus, E., Schroeder, S., Song, B., An, Y. C., Hyten, D. L., Nelson, R. L., et al. (2017) · The Plant Genome · doi:10.3835/plantgenome2016.10.0109 · Cited by 139
Genomic alterations of ERBB receptors in cancer: clinical implications
Mishra, R., Hanker, A. B., & Garrett, J. T. (2017) · Oncotarget · doi:10.18632/oncotarget.22825 · Cited by 132
The prognostic effects of somatic mutations in ER-positive breast cancer
Griffith, O. L., Spies, N. C., Anurag, M., Griffith, M., Luo, J. R., Tu, D., Yeo, B. J., Kunisaki, J., Miller, C. A., Krysiak, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05914-x · Cited by 137
Self-citationNussinov, R., Jang, H., Tsai, C., & Cheng, F. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006658 · Cited by 134
Metadata
- Authors
- Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., Fulton, L., Fulton, R. S., Zhang, Q., Wendl, M. C., Lawrence, M. S., Larson, D. E., Chen, K., Dooling, D. J., Sabo, A., Hawes, A. C., Shen, H., Jhangiani, S. N., Lewis, L. R., Hall, O., Zhu, Y., Mathew, T., Ren, Y., Yao, J., Scherer, S. E., Clerc, K., Metcalf, G. A., Ng, B., Milosavljevic, A., Gonzalez-Garay, M. L., Osborne, J. R., Meyer, R., Shi, X., Tang, Y., Koboldt, D. C., Lin, L., Abbott, R., Miner, T. L., Pohl, C., Fewell, G., Haipek, C., Schmidt, H., Dunford-Shore, B. H., Kraja, A., Crosby, S. D., Sawyer, C. S., Vickery, T., Sander, S., Robinson, J., Winckler, W., Baldwin, J., Chirieac, L. R., Dutt, A., Fennell, T., Hanna, M., Johnson, B. E., Onofrio, R. C., Thomas, R. K., Tonon, G., Weir, B. A., Zhao, X., Ziaugra, L., Zody, M. C., Giordano, T., Orringer, M. B., Roth, J. A., Spitz, M. R., Wistuba, I. I., Ozenberger, B., Good, P. J., Chang, A. C., Beer, D. G., Watson, M. A., Ladanyi, M., Broderick, S., Yoshizawa, A., Travis, W. D., Pao, W., Province, M. A., Weinstock, G. M., Varmus, H. E., Gabriel, S. B., Lander, E. S., Gibbs, R. A., Meyerson, M., & Wilson, R. K.
- Affiliations
- Washington University in St. Louis (US)
- Broad Institute (US)
- Baylor College of Medicine (US)
- Brigham and Women's Hospital (US)
- Dana-Farber Cancer Institute (US)
- Max Planck Society (DE)
- University of Michigan (US)
- The University of Texas MD Anderson Cancer Center (US)
- National Institutes of Health (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Meyerson, Matthew
- Wilson, Richard K.
- ORCID
- Ding, Li
- Getz, Gad
- Wheeler, David A.
- Mardis, Elaine R.
- McLellan, Michael D.
- Cibulskis, Kristian
- Greulich, Heidi
- Muzny, Donna M.
- Morgan, Margaret B.
- Fulton, Lucinda
- Fulton, Robert S.
- Wendl, Michael C.
- Lawrence, Michael S.
- Larson, David E.
- Chen, Ken
- Sabo, Aniko
- Shen, Hua
- Jhangiani, Shalini N.
- Zhu, Yiming
- Ren, Yanru
- Yao, Jiqiang
- Scherer, Steven E.
- Metcalf, Ginger A.
- Ng, Brian
- Milosavljevic, Aleksandar
- Tang, Yuzhu
- Koboldt, Daniel C.
- Lin, Ling
- Pohl, Craig
- Crosby, Seth D.
- Vickery, Tammi
- Winckler, Wendy
- Chirieac, Lucian R.
- Dutt, Amit
- Fennell, Tim
- Johnson, Bruce E.
- Thomas, Roman K.
- Tonon, Giovanni
- Zody, Michael C.
- Giordano, Thomas
- Roth, Jack A.
- Wistuba, Ignacio I.
- Ozenberger, Bradley
- Chang, Andrew C.
- Beer, David G.
- Watson, Mark A.
- Ladanyi, Marc
- Broderick, Stephen
- Yoshizawa, Akihiko
- Travis, William D.
- Pao, William
- Province, Michael A.
- Weinstock, George M.
- Varmus, Harold E.
- Gabriel, Stacey B.
- Lander, Eric S.
- Gibbs, Richard A.
- Meyerson, Matthew
- Wilson, Richard K.
- Venue
- Nature
- Published
- 2008-10
- Volume
- 455
- Issue
- 7216
- Pages
- 1069-1075
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2694412
- OpenAlex
- W2163798887
- Cited by
- 2,681
- References
- 54
- Citations by year
- 2026: 21 · 2025: 48 · 2024: 53 · 2023: 122 · 2022: 124 · 2021: 149 · 2020: 147 · 2019: 145 · 2018: 121 · 2017: 141 · 2016: 158 · 2015: 206 · 2014: 254 · 2013: 213 · 2012: 227
- FWCI
- 167.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Max Planck Institute for Plasma Physics (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- Broad Institute
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (U19CA084953, P50CA070907, R01CA154365)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung adenocarcinoma, somatic mutations, carcinogenesis, tyrosine kinase, EphA3, Eph receptors, KDR, NTRK, tumor suppressor, neurofibromatosis type 1, APC, RB1, ATM, PTPRD, LRP1B, smoking, DNA repair deficiency, signaling pathways, molecular targets, mutational landscape
- MeSH terms
- Adenocarcinoma, Bronchiolo-Alveolar, Female, Humans, Lung Neoplasms, Male, Mutation, Proto-Oncogenes, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Gene Dosage
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
